Literature DB >> 11466621

Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer.

M Scherl-Mostageer1, W Sommergruber, R Abseher, R Hauptmann, P Ambros, N Schweifer.   

Abstract

We report the identification of a novel human tumor associated gene, CDCP1 (Cub Domain Containing Protein), which was identified using representational difference analysis and cDNA chip technology. The gene consists of eight exons, the upstream region of which neither contains a TATA- nor a CCAAT-box. However, a CpG island is located around the transcription start, which is found in approximately 60% of known genes. The CDCP1 gene was mapped to chromosome 3p21-p23 by fluorescence in situ hybridization. For expression profiling real time quantitative RT--PCR was performed using cell lines and laser capture microdissected colon cancer biopsies. CDCP1 mRNA is approximately 6 kb and highly overexpressed in human colon cancer and lung cancer. CDCP1 represents a putative transmembrane protein, containing three CUB domains in the extracellular part most likely involved in cell adhesion or interacting with the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466621     DOI: 10.1038/sj.onc.1204566

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  57 in total

1.  Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling.

Authors:  Danislav S Spassov; Ching Hang Wong; Natalia Sergina; Deepika Ahuja; Michael Fried; Dean Sheppard; Mark M Moasser
Journal:  Mol Cell Biol       Date:  2010-12-28       Impact factor: 4.272

2.  The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.

Authors:  Ying Dong; Yaowu He; Leonore de Boer; M Sharon Stack; John W Lumley; Judith A Clements; John D Hooper
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

3.  Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state.

Authors:  Danislav S Spassov; Ching H Wong; Mark M Moasser
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

4.  The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.

Authors:  Danislav S Spassov; Frederick L Baehner; Ching Hang Wong; Stephen McDonough; Mark M Moasser
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

5.  CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.

Authors:  Heather J Wright; Jue Hou; Binzhi Xu; Marvin Cortez; Eric O Potma; Bruce J Tromberg; Olga V Razorenova
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

6.  CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis.

Authors:  Hui Liu; Shao-En Ong; Kwabena Badu-Nkansah; Jeffrey Schindler; Forest M White; Richard O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

7.  The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.

Authors:  C H Benes; G Poulogiannis; L C Cantley; S P Soltoff
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

8.  Adhesion signaling by a novel mitotic substrate of src kinases.

Authors:  Ami S Bhatt; Hediye Erdjument-Bromage; Paul Tempst; Charles S Craik; Mark M Moasser
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

Review 9.  The role of type II transmembrane serine protease-mediated signaling in cancer.

Authors:  Lauren M Tanabe; Karin List
Journal:  FEBS J       Date:  2016-12-24       Impact factor: 5.542

10.  Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells.

Authors:  Danislav S Spassov; Ching Hang Wong; Sunny Y Wong; Jeremy F Reiter; Mark M Moasser
Journal:  Cancer Res       Date:  2012-12-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.